Issue link: https://www.e-digitaleditions.com/i/1543258
Inhalation February 2026 41 3-month time window. e risk of asthma was elevated by 65.6%, the risk of allergic rhinitis by 27.2% and chronic rhinosinusitis by 74.4%. No risk increases were found for atopic dermatitis or eosinophilic esophagitis. Additional results showed COVID-19 vaccination reduced risks for respiratory T2IDs com- pared with controls. e risk of asthma decreased by 32.2% and smaller, but significant, risk decreases were seen for allergic rhinitis and chronic rhinosinus- itis. No impact on either atopic dermatitis or eosinophilic esopha- gitis was observed. Implications for public health e authors stated that, "as COVID-19 continues to circu- late globally, recurrent smaller infection waves of different SARS- CoV-2 variants pose ongoing challenges for health care systems. Infection sequelae, such as the higher risk for respiratory T2IDs shown [in their study] remain an important issue." Furthermore, they believe their results, "reinforce the importance of vaccination campaigns and public health messaging to address both direct and indirect conse- quences of COVID-19." References Content for this article was based on, excerpted and quoted from: • Olbrich H, Preuß S, Kridin K, et al. COVID-19 infection raises respiratory type 2 inflammatory disease risk, whereas vaccination is protective. Journal of Allergy and Clinical Immunology. August 12, 2025 online. DOI: 10.1016/j.jaci.2025.07.030. • Williams, A. Study links COVID-19 infections to increased asthma, allergy risk. August 22, 2025. https://www. fox29.com/news/covid-asthma- sinusitis-vaccine-study. Use the article archive FREE with no registration required.